Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$507.42 USD

507.42
841,844

+1.08 (0.21%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $507.62 +0.20 (0.04%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1

QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.

    Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance

    Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.

      Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive

      Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.

        Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise

        Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.

          DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View

          Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.

            Cardinal Health (CAH) Misses on Q3 Earnings, Lowers '18 View

            Cardinal Health (CAH) saw a tepid Q3 owing to declining profits at the Pharmaceutical unit despite a decent performance by the Medical segment.

              Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low

              Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.

                Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet

                Cardiovascular Systems' (CSII) peripheral device revenues continue to gain from a consistent strength in hospital setting.

                  Express Scripts (ESRX) Q1 Earnings Top, Patient Claims Fall

                  Express Scripts (ESRX) witnesses year-over-year declines in patient claims in Q1, thanks to the loss of certain public sector clients.

                    Pacific Biosciences (PACB) Loss Wider Than Expected in Q1

                    Pacific Biosciences (PACB) Q1 earnings and revenues miss estimates; Sequel orders rise.

                      Becton, Dickinson (BDX) Beats on Q2 Earnings, Lifts '18 View

                      Becton, Dickinson (BDX) gains on solid segmental performance in Q2; a raised guidance for fiscal 2018 encourages.

                        Cerner (CERN) Meets Q1 Earnings Estimates, Lowers '18 View

                        Lower revenues stemming from lesser-than-expected subscription bookings hurt Cerner's (CERN) Q1 results.

                          Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top

                          Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.

                            CVS Health's (CVS) Q1 Earnings Beat Estimate, Margins Grow

                            CVS Health's (CVS) year-over-year top line growth in the first quarter was primarily driven by a strong pharmacy services segment, benefiting from the upside in the specialty services.

                              AmerisourceBergen (ABC) Q2 Earnings Top, FY18 View Solid

                              AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and World Courier business in Q2.

                                NuVasive (NUVA) Q1 Earnings Miss Estimates, Revenues In Line

                                NuVasive (NUVA) gains on continued growth in international business along with strong case volume growth in the U.S. Hardware business in Q1.

                                  Ecolab (ECL) Q1 Earnings & Revenues Top, '18 Guidance Solid

                                  Solid performance in Global Industrial and Global Institutional segments gave a boost to Ecolab's (ECL) earnings and revenues in Q1.

                                    Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

                                    Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

                                      Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View

                                      Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.

                                        PerkinElmer (PKI) Q1 Earnings & Revenues Top, '18 View Up

                                        Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.

                                          athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q1

                                          Revenues in Business and Services along with a strong client base boost athenahealth's (ATHN) Q1 earnings.

                                            Hill-Rom (HRC) Earnings & Revenues Beat in Q2, Margins Up

                                            Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q2.

                                              Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4

                                              Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.

                                                ResMed (RMD) Q3 Earnings & Sales Beat on Overall Growth

                                                ResMed (RMD) beats earnings and sales in Q3 on solid contributions from domestic and international businesses.

                                                  Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1

                                                  Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.